Loading...
 
Toggle Health Problems and D

Basal Cell Carcinoma and Vitamin D


Basal Cell Carcinoma reduced when Vitamin D levels kept above 25 ng – June 2019

Assessing the Effect of Vitamin D Replacement on Basal Cell Carcinoma Occurrence and Recurrence Rates in Patients with Vitamin D Deficiency
Horm Cancer. 2019 Jun 28. doi: 10.1007/s12672-019-00365-2
Ince B1, Yildirim MEC2, Dadaci M1.

  • 1 Dept of Plastic & Reconstructive and Aesthetic Surgery, Meram Faculty of Medicine, Necmettin Erbakan University, 42080, Meram, Konya, Turkey.
  • 2 Dept of Plastic & Reconstructive and Aesthetic Surgery, Meram Faculty of Medicine, Necmettin Erbakan University, 42080, Meram, Konya, Turkey. dr.cem_yildirim at hotmail.com.


 Download the PDF from VitaminDWiki

The study aimed to determine whether 25-OH vitamin D3 deficiency is present in patients with diagnosed BCC, and the effect of vitamin D replacement on the rates of BCC recurrence in patients with 25-OH vitamin D3 deficiency. In this prospective study, between 2012 and 2017, in the first stage, 25-OH vitamin D3 levels of all patients diagnosed with BCC between 2012 and 2013 were evaluated. In the second stage between 2014 and 2015, we evaluated the 25-OH vitamin D3 level of patients who had 25-OH vitamin D3 level < 25 ng/mL. All the patients included in the second stage had BCC recurrence. In the third stage, the patients who were diagnosed 25-OH vitamin D3 deficiency with BCC, between 2015 and 2017, were studied. The mean 25-OH vitamin D3 level of the patients in the second stage was 10.12 ng/mL. Recurrence was observed in 9.64% of the patients in the second stage. The mean level of serum 25-OH vitamin D3 in the third stage was 40.1 ng/mL, and 3.49% of these patients presented with recurrence. In all the patients as the initial diagnosis and following the 25-OH vitamin D3 level in all the patients with BCC recurrence, maintaining 25-OH vitamin D3 levels above 25 ng/mL can significantly reduce the recurrence rate.


Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma - June 2024

Cancers 2024, 16(11), 2135; https://doi.org/10.3390/cancers16112135
Aurora Fernández-Galván 1,†,Pedro Rodríguez-Jiménez 1,2,*,†ORCID,Beatriz González-Sixto 3,María Teresa Abalde-Pintos 3 andBeatriz Butrón-Bris 1

Simple Summary
Basal Cell Carcinoma is the most prevalent cancer in the white population, with a 30% lifetime risk for individuals with fair skin. The main treatment goal is to completely remove the tumor while preserving function and appearance. Surgery is usually the preferred method due to its high success rates and the ability to verify that the entire tumor has been excised. However, topical and intralesional immunotherapy, although traditionally secondary to surgery, have demonstrated effectiveness and good cosmetic outcomes. These non-surgical treatments are valuable alternatives for patients who cannot undergo surgery. The objectives of this review are to summarize the current state of topical and intralesional immunotherapy treatments for BCC and to evaluate their potential as effective alternatives for certain patient populations.
Abstract
Basal Cell Carcinoma (BCC) is the most common type of cancer among the white population. Individuals with fair skin have an average lifetime risk of around 30% for developing BCC, and there is a noticeable upward trend in its incidence rate. The principal treatment objectives for BCC involve achieving the total excision of the tumor while maximizing the preservation of function and cosmesis. Surgery is considered the treatment of choice for BCC for two main reasons: it allows for the highest cure rates and facilitates histological control of resection margins. However, in the subgroup of patients with low-risk recurrence or medical contraindications for surgery, new non-surgical treatment alternatives can provide an excellent oncological and cosmetic outcome. An evident and justified instance of these local therapies occurred during the COVID-19 pandemic, a period when surgical interventions carried out in hospital settings were not a viable option.
 Download the PDF from VitaminDWiki


Skin Cancers and Vitamin D

Basal Cell Cancers predominate
Image


VitaminDWiki - Cancer category:


Cancers get less Vitamin D when there is a poor Vitamin D Receptor


VitaminDWiki – Topical Vitamin D category contains:

Topical is one of the many ways of increasing the vitamin D in your body
Topical is 2X to 50X more expensive than oral form
Topical is great for those who not want to swallow pillls nor fortifiy their food/drink with Vitamin D
Topical is one of the many gut-friendly forms of vitamin D (good bioavailability for those with poor guts
Topical is especially good form to apply directly to skin problems:
    - i.e. Psoriasis  Warts  Burns  Acne  Eczema  Wounds  (lasts about a day)
    The skin, like most tissues of the body, can fully-activate Vitamin D locally - no liver nor kidney needed.
Provides perhaps 100X higher concentration of Vitamin D to that portion than if same dose were taken orally
There were 98 topical Vitamin D products on Amazon Sept 2024 Creams, oils, patches, nanoemulsions, etc.
   I prefer Nutrasal nanoemulsion form
Suspect that topical Vitamin D is best absorbed where the skin gets Vitamin D naturally
- - - face and hands vs the back or the inside of arms
Nanoemulsions can also be applied topically under the tongue and inhaled


Might try treating BCC with topical Vitamin D, it treats many other skin problems

Try putting 1 or two drops of liquid vitamin D on a portion of BCC daily
See if there is any decrease in the BCC treated vs untreated after a month
My favorite topical Vitamin D is Nutrasal nanoemulsion


There have been 5701 visits to this page



Basal Cell Carcinoma and Vitamin D        
1392 visitors, last modified 12 Sep, 2024,
Printer Friendly Follow this page for updates

Attached files

ID Name Comment Uploaded Size Downloads
21745 Topical BCC_CompressPdf.pdf admin 12 Sep, 2024 137.81 Kb 15
12237 Basal Cell.pdf admin 30 Jun, 2019 266.42 Kb 579